BCL2 and lung cancer: Taken together, these findings suggest that combinatorial TP/HCPT drug regimens induce caspase-dependent apoptosis in A549 lung cancer cells mainly through modulating the Bax- and Bcl-2-triggered mitochondrial pathway.